Most healthtech companies don’t get into trouble for ignoring regulations. They get into trouble because they feel compliant.
That sense of comfort usually comes from having taken legal advice, checked the available framework, and ensured that nothing they are doing is explicitly prohibited.
In India’s healthtech environment, that kind of comfort can be misleading. Over time, I’ve noticed a recurring pattern in India’s healthtech space.
Companies rarely run into trouble because they ignore regulations. In most cases, they believe they are compliant, have taken legal advice, and are operating within the available framework.
The problem is not a lack of compliance. It is a misplaced sense of comfort. In healthtech, that comfort can be temporary.
A company may be doing everything “right” from a legal standpoint, and still find itself exposed when the regulatory lens shifts. By the time that shift becomes visible, the room to respond calmly is usually limited.
What makes this particularly difficult in healthtech is that the regulatory environment is not always clearly defined, but it is rarely static.
Across digital health, e-pharmacy, diagnostics, and medtech, a similar pattern tends to repeat.
Companies look for clarity in formal rules, notifications, or written guidance. If something is not explicitly restricted or if there is no immediate enforcement action, it is often treated as acceptable.
In practice, that is not how the system works.
Much of the real movement happens in areas where formal positions are still evolving. E-pharmacy continues to operate in a space where the regulatory position has never fully settled, yet business models have scaled on the assumption that the absence of a clear prohibition provides sufficient comfort.
At the same time, in digital health, advertising has become an increasingly sensitive area. Claims around outcomes, treatments, and services may be framed in ways that are commercially compelling, but begin to attract attention once concerns around patient safety and consumer protection start to build.
Individually, each of these developments may appear manageable. Taken together, they often point to something more important. The system is beginning to pay closer attention.
The mistake many companies make is to treat regulation as a binary question. Either something is allowed, or it is not.
Healthtech does not always operate in that binary.
A business may be legally defensible and still sit uncomfortably within the direction in which policy thinking is moving. By the time that direction becomes formal, the gap between what a company is doing and what is expected can become difficult to bridge quickly.
In my experience, companies that navigate this better tend to do a few things differently.
They do not rely only on formal clarity. They pay attention to how the conversation around their sector is evolving. They watch for early signs of discomfort, whether that comes from regulators, industry bodies, or public narratives.
They also recognise that healthtech sits closer to public interest than many other digital sectors. Issues of safety, trust, and accountability tend to move quickly from technical questions to policy concerns.
As a result, they adjust early. Sometimes that means moderating how they communicate. Sometimes it means rethinking parts of the business model before they become points of friction.
None of this guarantees that regulatory risk disappears. But it does reduce the likelihood of being caught off guard.
In India’s healthtech environment, the real risk is not that regulation will appear suddenly. It is that it will take shape gradually, in ways that are easy to overlook until it becomes difficult to respond.
Understanding that difference is what separates compliance from preparedness.
Leave a Reply